JPMorgan Chase & Co. Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price dropped by stock analysts at JPMorgan Chase & Co. from $275.00 to $245.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage presently has an “overweight” rating on the conglomerate’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.23% from the company’s previous close.

A number of other research firms also recently commented on DHR. KeyCorp reiterated an “overweight” rating on shares of Danaher in a research report on Thursday, January 29th. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 target price on shares of Danaher in a research report on Tuesday. Barclays reduced their price objective on Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Wells Fargo & Company reduced their price objective on Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, TD Cowen dropped their target price on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday. Eighteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.95.

Danaher Trading Down 1.8%

NYSE:DHR opened at $191.06 on Wednesday. The firm has a market cap of $135.22 billion, a P/E ratio of 37.89, a PEG ratio of 2.66 and a beta of 0.95. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. The stock’s 50 day simple moving average is $197.89 and its 200-day simple moving average is $214.56. Danaher has a 12-month low of $180.03 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the company posted $1.88 earnings per share. Danaher’s quarterly revenue was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Equities analysts anticipate that Danaher will post 8.4 EPS for the current year.

Insider Transactions at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the transaction, the executive vice president owned 5,099 shares in the company, valued at $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Danaher

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank bought a new position in Danaher in the 4th quarter valued at $2,177,106,000. Viking Global Investors LP raised its position in shares of Danaher by 543.9% in the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock worth $574,351,000 after acquiring an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Danaher by 104.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after purchasing an additional 2,216,789 shares during the period. Generation Investment Management LLP grew its stake in Danaher by 34.0% during the third quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock worth $1,319,354,000 after buying an additional 1,689,020 shares during the period. Finally, Wellington Management Group LLP grew its stake in Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after buying an additional 1,517,904 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and guidance lift — Danaher reported $2.06 EPS (above consensus) and raised FY26 EPS guidance to $8.35–8.55, signaling confidence in biotech and life‑sciences momentum; this is the main bullish driver. Danaher beats first-quarter profit estimates on strong bioprocessing demand
• Positive Sentiment: Bioprocessing and life‑sciences strength — management highlighted double‑digit momentum in bioprocessing and continued strength in life‑sciences tools, which should support margin expansion and cash generation. Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
• Neutral Sentiment: Investor materials and transcripts available — the company posted a press release, slide deck and a full earnings‑call transcript; useful for modeling segment trends and the acquisition roadmap but no immediate surprise. View Press Release / Slide Deck
• Neutral Sentiment: Strategic M&A focus — coverage notes Danaher’s acquisition strategy (including the Masimo-related work) as an important growth lever; strategic but timing and integration risk remain to be tracked. DHR Q1 deep dive: Bioprocessing momentum and acquisition strategy drive mixed start to 2026
• Negative Sentiment: Revenue slightly missed estimates — Q1 revenue was $5.95B vs. ~ $6.0B consensus, and that shortfall was cited as a reason for near‑term share weakness. Danaher (NYSE:DHR) Misses Q1 CY2026 Revenue Estimates
• Negative Sentiment: Diagnostics and respiratory softness — multiple reports flagged weakness in diagnostics and a lowered respiratory outlook, which could pressure near‑term organic growth until end markets recover. Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.